Chronic Idiopathic Constipation (CIC) Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Chronic idiopathic constipation is a functional gastrointestinal disorder which leads to difficulty in defecating. It is a more chronic or severe condition and the symptoms of the disease include bloating, abdominal discomfort, hard stool, incomplete evacuation, gastric pain, and strain during the bowel movement. It is an idiopathic condition due to the causes of the disease are unclear, however, it may cause due to psychological, neurological, and psychosomatic conditions. Chronic idiopathic constipation is majorly caused in the adults or geriatric people. Diagnosis of CIC is difficult due to the lack of physiological causes and physicians look for symptoms like weight, blood in stool, and low blood count among others.


Increase in the prevalence of chronic idiopathic constipation due to change in lifestyle and food habits, rise in awareness about the CIC treatment, increase in the demand for CIC drugs, and availability of the over-the-counter CIC drugs in the market are driving the chronic idiopathic constipation treatment market. Moreover, various pipeline drugs for the CIC treatment and frequent product approvals from various drug regulatory bodies are propelling the chronic idiopathic constipation treatment market. However, lack of physiological symptoms for the disease and less number of drugs available for CIC treatment are the factors anticipated to hinder the growth of chronic idiopathic constipation treatment market.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

Chronic idiopathic constipation treatment market is segmented on the basis of the drug class, route of administration, distribution mode, and distribution channel

Based on the drug class, Chronic idiopathic constipation treatment market is segmented into the following:
• Emollients
• Laxatives
• Bulk-forming agents
• Chloride channel activators
• Osmatic products
• Others

Based on the route of administration, Chronic idiopathic constipation treatment market is segmented into the following:
• Oral
• Parenteral

Based on the distribution mode, Chronic idiopathic constipation treatment market is segmented into the following:
• Prescription mode
• Over-the-counter drugs

Based on the distribution channel, Chronic idiopathic constipation treatment market is segmented into the following:
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Drug Stores

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/#ulp-c654SbFYO64MsOhu

Chronic idiopathic constipation (CIC) treatment market is growing at a significant CAGR owing to recent product approvals and competitors focus on the development of newer drugs for CIC treatment. Moreover, increase in the prevalence of chronic idiopathic constipation cases also expected to propel the market revenue over the forecast period. Acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by the companies for increasing their revenue share in the market. For instance, In January 2017, FDA approved Trulance manufactured by Synergy Pharmaceuticals used in the treatment of chronic idiopathic constipation.

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/#ulp-14mlyhjMGhVjZqa3

Geographically, chronic idiopathic constipation treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America has a significant share in chronic idiopathic constipation treatment market owing to increase in the prevalence if CIC disease (according to National Institute of Health, approximately 63 Mn people affected with CIC in U.S.), change in lifestyle, recent FDA approvals for CIC treatment drugs, and increase in healthcare expenditure. In Europe, increase in aging population, rise in R&D activities for CIC treatements, availability of over-the-counter CIC drugs, and increase in per capita income might bolster the chronic idiopathic constipation treatment market. However, Asia Pacific exhibiting lucrative growth owing to the rise in geriatric population, and increase in adoption of CIC treatments.


Some of the players in Chronic Idiopathic Constipation (CIC) Treatment market are GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Allergan Plc. (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma, Inc. (Japan), synergy pharmaceuticals, Inc. (U.S.), Sanofi S.A. (France), and Pfizer, Inc. (U.S.) to name a few.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.